Family of large biological molecules
POPULARITY
Categories
108 episodes with RNA
65 episodes with RNA
76 episodes with RNA
25 episodes with RNA
142 episodes with RNA
27 episodes with RNA
28 episodes with RNA
42 episodes with RNA
26 episodes with RNA
14 episodes with RNA
15 episodes with RNA
19 episodes with RNA
10 episodes with RNA
24 episodes with RNA
11 episodes with RNA
36 episodes with RNA
11 episodes with RNA
13 episodes with RNA
9 episodes with RNA
10 episodes with RNA
28 episodes with RNA
16 episodes with RNA
16 episodes with RNA
11 episodes with RNA
7 episodes with RNA
6 episodes with RNA
8 episodes with RNA
7 episodes with RNA
9 episodes with RNA
11 episodes with RNA
11 episodes with RNA
9 episodes with RNA
6 episodes with RNA
12 episodes with RNA
14 episodes with RNA
18 episodes with RNA
6 episodes with RNA
4 episodes with RNA
10 episodes with RNA
162 episodes with RNA
4 episodes with RNA
7 episodes with RNA
5 episodes with RNA
4 episodes with RNA
12 episodes with RNA
10 episodes with RNA
150 episodes with RNA
11 episodes with RNA
5 episodes with RNA
8 episodes with RNA
8 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
6 episodes with RNA
10 episodes with RNA
6 episodes with RNA
4 episodes with RNA
6 episodes with RNA
7 episodes with RNA
6 episodes with RNA
7 episodes with RNA
8 episodes with RNA
5 episodes with RNA
3 episodes with RNA
7 episodes with RNA
6 episodes with RNA
3 episodes with RNA
15 episodes with RNA
4 episodes with RNA
5 episodes with RNA
8 episodes with RNA
4 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
8 episodes with RNA
3 episodes with RNA
7 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
7 episodes with RNA
8 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
6 episodes with RNA
7 episodes with RNA
19 episodes with RNA
5 episodes with RNA
14 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
3 episodes with RNA
4 episodes with RNA
10 episodes with RNA
6 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
5 episodes with RNA
5 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
3 episodes with RNA
12 episodes with RNA
6 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
2 episodes with RNA
3 episodes with RNA
3 episodes with RNA
8 episodes with RNA
5 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
6 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
4 episodes with RNA
3 episodes with RNA
8 episodes with RNA
3 episodes with RNA
3 episodes with RNA
2 episodes with RNA
4 episodes with RNA
3 episodes with RNA
Dr. Phil Cardoso talks with Dr. Peter Erickson and Tess Stahl of the University of New Hampshire about the effects of feeding diets containing supplementary sodium butyrate and monensin on growth performance, nutrient digestibility, and health in postweaned heifers. Links to papers mentioned in this episodeStahl TC, Hatungimana E, Klanderman KD, Moreland SC, Erickson PS. 2020. Sodium butyrate and monensin supplementation to postweaning heifer diets: Effects on growth performance, nutrient digestibility, and health.DOI: 10.3168/jds.2020-18584https://www.journalofdairyscience.org/article/S0022-0302(20)30720-7/fulltextRice EM, Aragona KM, Moreland SC, Erickson PS. 2019.Supplementation of sodium butyrate to postweaned heifer diets: Effects on growth performance, nutrient digestibility, and health.DOI: 10.3168/jds.2018-15525https://pubmed.ncbi.nlm.nih.gov/30738684/Górka P, Kowalski ZM, Zabielski R, Guilloteau P. 2018. Invited review: Use of butyrate to promote gastrointestinal tract development in calves.DOI: 10.3168/jds.2017-14086https://www.sciencedirect.com/science/article/pii/S0022030218302212Kononoff PJ. Snow DD, Christiansen DA. 2017. Drinking Water for Dairy Cattle. Pages 611–624 in Large Dairy Herd Management.DOI: 10.3168/ldhm.0845https://ldhm.adsa.org/Rosa F, Busato S, Avaroma FC, Linville K, Trevisi E, Osorio JS. 2018. Transcriptional changes detected in fecal RNA of neonatal dairy calves undergoing a mild diarrhea are associated with inflammatory biomarkers.DOI: 10.1371/journal.pone.0191599https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191599Hatungimana E, Stahl TC, Erickson PS. 2020. Growth performance and apparent total tract nutrient digestibility of limit-fed diets containing wet brewer's grains to Holstein heifers.DOI: 10.1093/tas/txaa079https://academic.oup.com/tas/article/4/3/txaa079/5855081
Welcome back to America's #1 Daily Podcast, featuring America's #1 Real Estate Coaches and Top EXP Realty Sponsors in the World, Tim and Julie Harris. Ready to become an EXP Realty Agent and join Tim and Julie Harris? Visit: https://whylibertas.com/harris or text Tim directly at 512-758-0206. ******************* 2025's Real Estate Rollercoaster: Dodge the Career-Killers with THIS Mastermind!
Dzięki sztucznej inteligencji i na podstawie danych RNA można przewidzieć chorobę lub powiedzieć coś o stanie zaawansowania dolegliwości - mówi w studiu TOK FM prof. Ewa Bartnik. Ekspertka jest biolożką i genetyczką z Instytutu Genetyki i Biotechnologii Uniwersytetu Warszawskiego, członkinią Komitetu Genetyki Człowieka i Patologii Molekularnej Polskiej Akademii Nauk.
Send us a textIn this compelling episode of Coffee in the Barn, Dr. Casey Bradley sits down with molecular biologist and biotech entrepreneur Dr. Howard Urnovitz to uncover a revolutionary perspective on human and animal health. Driven by a deeply personal mission, Dr. Urnovitz shares his journey from developing groundbreaking diagnostics—including the first FDA-approved urine test for HIV—to launching FBB Biomed, a company that leverages RNA sequencing and artificial intelligence to detect disease long before symptoms appear.From the misunderstood role of “junk DNA” and endogenous viruses to the impact of environmental toxins on gene expression, this episode challenges conventional thinking about disease, diagnostics, and the true potential of genomics. Dr. Urnovitz also discusses his provocative new book Unnatural Selection, which connects the dots between historical pandemics, agricultural practices, and modern health crises.Whether you're a student, scientist, producer, or policy advocate, this episode is packed with insights that will inspire you to think differently about how we safeguard the health of our animals, ourselves, and our planet.☕ So grab your coffee—and join us as we explore the frontier where science, storytelling, and systems thinking collide.To learn more about Poultry Lingo 2025, email technical@animistic.co Please email technical@animistic.co to learn more about our regulatory packages. Visit animistic.co to learn more.Support the showConnect with us on Facebook, Instagram and LinkedIn:@cofeeinthebarn
Episode: 2934 Reading the Molecules of Life. Today, we read the molecules of life.
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.
Alberto Vazquez-Salazar, PhD, is a NASA postdoctoral fellow working at UCLA in the lab of Professor Irene Chen. He studies how life may have started on Earth by focusing on a molecule called RNA, or ribonucleic acid, which is a critical molecule that exists in all living things. His work is a part of astrobiology that explores how life began on Earth and how we might find signs of life elsewhere in the universe. In this episode of Further Together, Vazquez-Salazar talks to host Michael Holtz about how science has always seemed to be part of his life. Growing up in Mexico City, his mom, a botanist, kept books and plant specimens everywhere. “Science was just part of everyday life,” he says. “It was as normal as finding cereal in the pantry.” Listen to learn more about Vazquez-Salazar's journey to NASA. To learn more about the NASA Postdoctoral Program and when applications open, visit https://npp.orau.org/index.html
Miðvikudagur 11. júní Flugvöllurinn, hafið, reynsluboltar, glæpasamtök, huldufólk og umbylting í læknavísindum Daði Rafnsson hjá samtökunum Hljóðmörk sem berjast gegn óþarfa flugumferð á Reykjavíkurflugvelli og Ólafur Hjálmarsson hljóðverkfræðingur ræða við Björn Þorláks stöðu vallarins, vítaverða og vaxandi hljóðmengun og alvarlegt atvik í gærkvöld. Flugvallarvinir hafa hótað fólki sem vill minnka umferð um völlinn að því er kemur fram í umræðunni. Kristín Vala Ragnarsdóttir, sérfræðingur í sjálfbærni og prófessor emerita í jarðvísindadeild Háskóla Íslands, ræðir við Oddnýju Eir um aðgerðarleysi og hugsanavillur tengdum hagvexti sem ógna hafinu og framtíð okkar. Reynsluboltar vikunnar voru þingkonurnar fyrrverandi; Álfheiður Ingadóttir, Kristín Ástgeirsdóttir og Oddný Harðardóttir. Rætt var um helstu fréttir og stjórnmál. Ekki síst að það vanti fólk á þingi sem talar frá vinstri og hefur áhuga á náttúruvernd. Guðmundur Ingi Þóroddsson, formaður Afstöðu, félags fanga, ræðir við Maríu Lilju um glæpasamtök útlendinga í fangelsi og auknar valdheimildir lögreglu. Auður Aðalsteinsdóttir, bókmenntafræðingur, höfundur, rannsóknarlektor og forstöðumaður Rannsóknaseturs Háskóla Íslands í Þingeyjarsveit segir okkur frá nýjum rannsóknum á tengslum sköpunarkrafts og náttúru og hlutverki álfa, huldufólks í pólitík og menningu samtíma okkar. Páll Þórðarson, efnafræði-prófessor við háskóla í Sydney í Ástralíu segir Gunnari Smára frá umbyltingu í læknisfræði vegna RNA-tækni sem hann vinnur að.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.
Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book. Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer. On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited. While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results. And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this. Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas. On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes. Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program. In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system. In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense. So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers. We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer. We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost. In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer. So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future. A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology. We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode. Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Nathan Pennell @n8pennell @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Nate Pennell: Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics
In this bite-sized H-Files episode, I unpack 5 hard-won lessons from my conversation with Nigel Theobald, CEO of N4 Pharma.After a decade of building a biotech platform for RNA delivery, Nigel knows exactly how brutal, and how rewarding this space can be.You'll walk away with:The one sentence every founder must write downWhy you can't bootstrap biotechHow to pivot with purposeThe truth about investor trustAnd why execution matters more than competitionHit play and take notes. Your future self will thank you.
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
Experts highlight innovative research and clinical advances in fertility and infertility. Speakers share new ways to improve IVF outcomes using liquid biopsy and RNA analysis, aiming to predict embryo quality without invasive tests. They also explore how imaging technologies can better detect and monitor reproductive cancers, helping tailor treatments for conditions like ovarian and cervical cancer. Throughout, there's a focus on addressing health disparities, improving care for all genders, and using big data and AI to personalize reproductive health solutions. Antoni Duleba, M.D. Clinical Landscape and OGRS Opportunities Rebecca Rakow Penner, M.D.,Ph.D. Imaging in Gynecologic Disorders Jennifer Anger, M.D.,M.P.H. Interstitial Cystitis/Bladder Pain Syndrome in Reproductive Age Women Sheng Zhong, Ph.D. Silverseq and Liquid Biopsy Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40667]
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli Lilly and Rznomics in the field of RNA-editing therapies, and a potential quality-of-life breakthrough for patients with Parkinson's. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
What does it really take to bring a biotech product to market?Nigel Theobald, founder and CEO of N4 Pharma, joins me to share the real highs and lows of turning science into a scalable business.We dive into:The challenges of RNA drug deliveryHow to stay resilient when plans changeBuilding a virtual, world-class teamThe path from platform to productThis is a must-listen for anyone in biotech, medtech, or startup life.
Kara Werner, VP & GM at Tempus AI, joins Kellogg MBA student Ashley Lemon to discuss how Tempus makes patient data meaningful - enabling earlier cancer diagnoses and accessible precision medicine. They also discuss Kara's career journey at the healthtech startup and advice for MBAs looking to break into the space.LinkedInTimestamps:(1:47) Kara's why: from Kellogg to Tempus AI(4:17) Fixing what's broken: structuring and operationalizing multimodal patient data(10:08) Tempus's edge: RNA & DNA, AI-enabled diagnostics platform & strategic partnerships (14:58) AI in action: how Tempus One, Lens & Next connect patients to trials and testing to close care gaps(18:27) Standing up pharma biz: building and adapting for a new client(26:02) What Kara's excited about: tissue-sparing RNA for identifying ADC candidates(28:55) MBA advice: taking Medvec's Negotiations, welcoming challenge, pivoting with purpose(36:24) Wildest & craziest dream: travel experience curator!Visit our podcast page for more episodes on trends and innovation in healthcare and follow our socials so you never miss an update.
Broadcast from KSQD, Santa Cruz on 5-22-2025: Dr. Dawn explores groundbreaking cancer research using high-throughput "digital twin" analysis to reverse colon cancer cells back to normal states, identifying three master molecular switches that can induce normal cell differentiation without killing the cancer cells, thus avoiding traditional chemotherapy side effects. She discusses remarkable results from Memorial Sloan Kettering showing 80% of patients with mismatch repair deficient tumors, including all 49 rectal cancer patients, saw complete tumor disappearance after six months of dostarlimab immunotherapy, with no recurrence at five years and minimal side effects. The program covers innovative CRISPR applications, including targeting previously "undruggable" cancer mutations like KRAS and BRAF by selectively degrading mutant RNA messages while preserving healthy genes, offering unprecedented precision in cancer treatment. Dr. Dawn explains a clever immunotherapy approach that disguises tumors as pig organs using Newcastle disease virus carrying alpha-gal enzyme, tricking the immune system into mounting fierce attacks against cancer cells, showing promising results in both monkey and human trials. She describes fascinating research using cryoshocked tumor cells as Trojan horses, where liquid nitrogen-treated cancer cells carrying CRISPR gene editing tools directly seek out tumors, offering superior targeting compared to injecting CRISPR. The show reveals how cancers create protective acid walls around themselves to repel immune cells, with individual cancer cells pumping lactic acid away from the tumor center to form pH 5.3 barriers that kill attacking CD8 T cells within hours. Dr. Dawn discusses breakthrough mRNA cancer vaccines for glioblastoma using patients' own tumor cells, showing rapid immune system activation within 48 hours and extending survival in both dogs and humans with this aggressive brain cancer. She explores the "flower code" mechanism where cancer cells gaslight healthy cells through epigenetic manipulation, expressing dominant "flower win" codes to overpower normal cells expressing "flower lose" codes in biological turf wars. The program addresses systemic problems in cancer classification, explaining how organ-based categorization delays access to effective treatments, with patients waiting years for drugs that could help based on molecular profiles rather than tumor location. Dr. Dawn concludes by highlighting medical discrimination against people with Duffy null phenotype, primarily affecting African Americans, whose naturally lower neutrophil counts lead to reduced chemotherapy doses and excluded clinical trial participation despite no increased infection risk.
올뉴 삼테성즈! 2025년 5월호. 스페인 정전과 재생에너지 그리고 중국의 미사일 기술-오프닝 PPL노벨상 수상자가 직접 쓴 RNA의 모든 것, 'RNA의 역사'!- 오로라 여행 매진! 대기 예약 링크는 아래에.https://www.sciencepeople.co.kr/39684-2/- 이용의 디벼보기스페인 정전 사태로 짚어 본 우리나라 재생에너지 발전의 허와 실- K2 박사인도 공군의 라팔을 격추한 파키스탄 공군의 중국제 미사일, 그 기술을 알아보다- 전체 자료https://www.slideshare.net/slideshow/2025-5-pdf/279475466- 과학과사람들 회원 '사람들' 가입 링크https://www.sciencepeople.co.kr/membership/about-membership/과학과 사람들 제공
We've talked before about how government policy has prevented the egg industry from using vaccines to fight Highly Pathogenic Avian Influenza. But if there was a policy shift tomorrow, and producers were given the green light to immunize their birds, what would that effort even look like? Where would the vaccines comes from? How would we know they're safe and effective? How much would they cost? And who would be expected to foot that bill?Joel Harris is the co-founder of Genvax. An economist by trade, he has nearly 20 years of experience working in the field of animal vaccine development. His company, Genvax, uses an RNA platform that allows them to quickly develop vaccines, and respond rapidly to emerging diseases. Today, Joel walks us through the complex logistics and economics of vaccine development, as well as his own companies efforts to develop a tool to fight HPAI. This is a fascinating issue that sits at the intersection of business, politics and science. Joel does a great job of breaking it all down for us, and shedding light on the inner workings of a niche but vital industry. Are you an egg industry pro? Reach out to be a guest on the show! Connect with us on LinkedIn and Instagram. And please rate Eggheads on Spotify and Apple Podcasts.If you're interested in sponsoring a future episode of Eggheads, you can contact us by filling out this form.
Dana Foss and Ross Wilson are the cofounders of Editpep, a biotech startup focused on developing CRISPR-based therapeutics. They are using a proprietary peptide-based delivery platform that enables targeted delivery to specific cell types, particularly for hard-to-reach areas like the brain. While Dana Foss is the CEO, Ross Wilson is also an Assistant Adjunct Professor of Molecular and Cell Biology and also the Director of Therapeutic Delivery at the Innovative Genomics Institute at the University of California, Berkeley. He is one of those very few academics that co-founded a startup and is very active in building Editpep. Ross explains how he does it all so well! Dana was previously a postdoc in Ross Wilson's lab, where she developed the technology. Ross was a postdoc in Nobel Laureate Jennifer Doudna's lab. Now he has his own lab and collaborates with Jennifer Doudna at the Innovative Genomics Institute. In this episode of lab to startup, we will explore their initial decisions that lead to launching the startup; existing CRISPR delivery technologies, their challenges, and then do a deep dive into their delivery technology. opportunities,; fundraising efforts, and their future goals. Shownotes https://www.editpep.bio/ CRISPR Delivery problem and current solutions Existing solutions like AV, LNPs are mostly limited to mice Ribonucleoprotein, a complex of RNA and protein (RNP): Technology deep dive Outsiders bringing in fresh perspective Dana transitioning out of academia: working on a shared goal Hard to shepard the technology towards the patient by depending on a third party Self motivation and gumption: Ways to move technologies out of the lab Early stage co-founder chemistry Ross's innovative role being an academic and entrepreneur Fundraising journey Open mindedness to non-traditional investors Investors: Berkeley Skydeck, Lindonlight Collective Filters for selecting investors Getting to market: Parallels from other delivery companies like Alnylam Counterintuitive decisions Future goals Connecting the dots
Alexandre Garcia comenta sobre os valores descontados indevidamente de aposentados e pensionistas, que devem superar os R$ 6,3 bilhões. Garcia também questiona os empréstimos do BNDES para a Venezuela, que não vai pagar o que deve. Ele ainda fala sobre as enchentes do Rio Grande do Sul e a vacina de RNA contra a Covid.
In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs. Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery. Chapter Summaries;00:00 Introduction to John Maraganore: Biotech Trailblazer01:11 John's Early Life and Education03:09 Joining Alnylam and the RNAi Revolution04:56 Challenges and Successes at Alnylam06:47 Current Biotech Funding Environment08:17 Global Competition and US Leadership in Biotech10:25 The Importance of In-Person Collaboration12:01 Overcoming Drug Delivery Hurdles15:21 Maintaining an Entrepreneurial Spirit in Biotech17:00 Balancing Science and Business in Decision Making20:27 Strategic Partnerships in Biotech23:36 The Role of Biotech in Global Challenges26:25 Advocating for Policy Changes in Biotech30:41 Mentoring the Next Generation of Biotech Leaders32:35 Future Frontiers in Biotech Innovation36:08 John's Vision for the Future of Biomedicine37:18 Communicating Innovation and LeadershipDon't forget to Like, Share, Subscribe, Rate, and Review! Keep up with John Maraganore;LinkedIn: https://www.linkedin.com/in/john-maraganore/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now.
Send us a textDr. Michael Koren shares exciting news about the revival of an oral COVID vaccine study previously halted by government spending cuts. The non-mRNA vaccine trial represents an important alternative approach that apparently received priority status even under strict budget reviews.• Oral COVID vaccine study in Jacksonville now actively enrolling participants after being temporarily halted by DOGE initiative• Study offers a non-mRNA alternative that might appeal to those concerned about messenger RNA technology• Summer months in Florida paradoxically see increases in respiratory infections as people spend more time indoors with air conditioning• Dr. Koren explains why most vaccines require injection rather than oral delivery• Discussion of pharmaceutical pricing disparities between US and other countries• The "innovation premium" Americans pay funds research that benefits the global population• Finding balance between incentivizing medical breakthroughs and ensuring fair cost distribution remains challengingFor reliable, unbiased medical information, visit MedEvidence.com. To learn more about participating in the oral COVID vaccine study or other clinical trials, visit EncoreDocs.com.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!
This episode teaches that innovation is born at the intersection of curiosity and persistence. Dr. Gudrun Stengel, co-founder and CEO of Alida Biosciences, reveals how her startup is transforming the landscape of RNA research through a novel technology called proximity barcoding. Dr. Stengel's story exemplifies the power of entrepreneurial spirit in driving scientific discovery, offering a glimpse into how one idea can reshape an entire field.At Alida Biosciences, Dr. Stengel and her team are pioneering new tools for detecting RNA modifications, a largely unexplored realm of epigenetics. Using their proximity barcoding platform, researchers can read multiple RNA modifications simultaneously, uncovering potential biomarkers and therapeutic targets for diseases like cancer, Alzheimer's, and diabetes. This technology bridges a critical gap in multiomics, allowing scientists to dive deeper into how epigenetic changes influence gene expression and cellular behavior.Beyond the lab, Dr. Stengel shares her experience as a first-time founder, balancing scientific rigor with startup life. From managing a team to fundraising, her journey underscores the importance of resilience, optimism, and maintaining a long-term vision. She also offers valuable advice for budding scientists, encouraging them to embrace challenges and remain persistent in the face of setbacks. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Picture this, a tiny, 30 nm, relentless RNA virus named norovirus slips into your life, uninvited, and turns your gut into a battlefield. It's not the flu. Forget that “stomach flu” misnomer. It's a Caliciviridae family member, a nonenveloped, single-stranded RNA ninja that thrives in making chaos. As a pediatrician, I've seen it wreak havoc in kids and parents alike, and it's a master of surprise. It just played Risk in my GI tract last week. Not Fun! Let's unpack how it infects, spreads, and toys with us humans, straight from the AAP's Red Book (2024) and other research. Norovirus causes an estimated 1 in 15 US residents to become ill each year as well as 71,000 hospitalizations and 800 deaths annually, predominantly among young children and the elderly. Norovirus doesn't knock, more so it sneaks in, needing under 100 viral particles to ignite trouble. You're sipping contaminated water, munching an oyster from a shady bay, or your toddler's unwashed hands after a playdate deliver the payload. It's mostly fecal-oral, stool to mouth via food, water, or surfaces. But don't sleep on aerosolized vomit. One hurl in a crowded daycare, and airborne particles linger, landing on toys, doorknobs, you name it for days. Did I say lingering! Smart viral spread! Gorilla warfare is on! Dr. M
While the world is still coming to terms with the effects the mRNA products have had on those who have taken them — and on those who have not — something even more dangerous is being rolled out: Self-Amplifying RNA products.Canadian researcher Dr. Jessica Rose has dug deep into the topic. In this interview, I ask her to explain exactly what SA RNA is, how it is different from the mRNA technology, and why it could be dangerous.We also talk about shedding, from both SA RNA and mRNA, and about the actions each of us can take to protect ourselves, and keep ourselves strong and healthy in the midst of all this — quite frankly — lunacy.Dr. Rose holds a a bachelor's degree in applied mathematics, a masters in immunology, a PhD in computational biology, and post-doctorate degrees in molecular biology and biochemistry.You can find her work on Substack, here and here.Some of her articles on self-amplifying RNA can be found here, here, and here.She spoke about the self-amplifying RNA technology at the National Citizens Inquiry in Vancouver, 2024.
In this 2025 spring beekeeping update, Jeff and Becky gather beekeepers from across the country for a timely check-in on seasonal progress, survival rates, and challenges. Joining the table are Ang Roell (MA/FL), Bonnie Morse (CA), Duane Combs (AZ), and Jay Williams (TN), each offering a candid look at their spring buildup after a winter marked by extremes. Topics include overwintering survival—ranging from Duane's 70% losses in Arizona to Jay's impressive 96% survival in Tennessee—and how weather volatility and hive nutrition played pivotal roles. The conversation dives into spring splits, swarm control, queen longevity, and promising new varroa treatments like VarroxSan and RNA-based controls in development. Jay shares the results of using VarroxSan in his operation, while others discuss balancing cost and effectiveness with homemade oxalic pads and breeding practices. The episode also explores instrumental insemination, drone saturation strategies, and queen selection across climates. With thoughtful input from across the country, this roundtable offers insights that every beekeeper—regardless of location—can reflect on as spring rolls into full bloom. Websites from the episode and others we recommend: Honey Bee Obscura Bee Rooms Episode as mentioned by Becky: https://honeybeeobscura.com/225 Honey Bee Health Coalition: https://honeybeehealthcoalition.org The National Honey Board: https://honey.com Honey Bee Obscura Podcast: https://honeybeeobscura.com Copyright © 2025 by Growing Planet Media, LLC ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com This episode is brought to you by Global Patties! Global offers a variety of standard and custom patties. Visit them today at http://globalpatties.com and let them know you appreciate them sponsoring this episode! Thanks to Bee Smart Designs as a sponsor of this podcast! Bee Smart Designs is the creator of innovative, modular and interchangeable hive systems made in the USA using recycled and American sourced materials. Bee Smart Designs - Simply better beekeeping for the modern beekeeper. Thanks to Dalan who is dedicated to providing transformative animal health solutions to support a more sustainable future. Dalan's vaccination against American Foulbrood (AFB) is a game changer. Vaccinated queens protect newly hatched honeybee larvae against AFB using the new Dalan vaccine. Created for queen producers and other beekeepers wanting to produce AFB free queens. Retailers offering vaccinated queens and packages: https://dalan.com/order-vaccinated-queens/ More information on the vaccine: https://dalan.com/media-publications/ Thanks to Strong Microbials for their support of Beekeeping Today Podcast. Find out more about their line of probiotics in our Season 3, Episode 12 episode and from their website: https://www.strongmicrobials.com Thanks for Northern Bee Books for their support. Northern Bee Books is the publisher of bee books available worldwide from their website or from Amazon and bookstores everywhere. They are also the publishers of The Beekeepers Quarterly and Natural Bee Husbandry. _______________ We hope you enjoy this podcast and welcome your questions and comments in the show notes of this episode or: questions@beekeepingtodaypodcast.com Thank you for listening! Podcast music: Be Strong by Young Presidents; Epilogue by Musicalman; Faraday by BeGun; Walking in Paris by Studio Le Bus; A Fresh New Start by Pete Morse; Wedding Day by Boomer; Christmas Avenue by Immersive Music; Red Jack Blues by Daniel Hart; Original guitar background instrumental by Jeff Ott. Beekeeping Today Podcast is an audio production of Growing Planet Media, LLC Copyright © 2025 by Growing Planet Media, LLC
This special lipid-themed issue of JACC emphasizes the importance of innovative research in lipid disorders to reduce cardiovascular risk, highlighting studies that extend our understanding of lipid biology and evaluate new treatments. Key reviews and original investigations explore novel lipid-modifying therapies, such as RNA interference and antibody therapies, demonstrating their potential in managing complex lipid disorders. The issue also includes editorials and case studies that provide critical context and underscore the need for personalized and mechanism-driven approaches in lipid management.
Broadcast from KSQD, Santa Cruz on 5-08-2025: Dr. Dawn examines groundbreaking research on rising rates of early-onset colorectal cancer worldwide, explaining how researchers have identified a bacterial toxin called colibactin produced by specific E. coli strains that appears to cause early genetic mutations in cancer-controlling genes, potentially explaining why younger generations face significantly higher cancer risks. She discusses how modern medical practices like antibiotic overuse and cesarean deliveries may disrupt protective gut microbiomes, while diets low in fiber and high in animal fats create conditions where harmful bacteria thrive and damage the protective mucosal barrier, potentially exposing colon cells to cancer-causing mutations. Dr. Dawn explains fascinating research on transgenerational memory in C. elegans worms and mice, where learned aversions to specific odors are genetically passed down to offspring through epigenetic mechanisms involving methylation and RNA pathways, challenging traditional views on inheritance and suggesting implications for human genetics. Responding to an email about posterior tibial tendon disease (PTTD), she offers comprehensive management strategies including cross-massage with ice, proper footwear selection, careful stretching techniques, and anti-inflammatory approaches while cautioning against invasive procedures like steroid injections that might weaken tendons. She discusses promising research on rosemary's potential in Alzheimer's treatment, explaining how carnosic acid activates the NRF2 pathway that controls antioxidant proteins, with researchers developing a more stable chemical analog that reduced inflammation and improved memory in mouse models of Alzheimer's disease. Dr. Dawn provides updates on vaccination recommendations, noting that egg allergy questions are no longer needed before flu vaccines, pneumococcal vaccines are now recommended for all adults over 50, and explaining the small risk of Guillain-Barré syndrome with RSV vaccines compared to the much larger risk of RSV-related deaths. She shares information about a new hypertension risk calculator called PREVENT that reclassifies many patients to lower risk categories, potentially allowing 2.6 million Americans to manage their blood pressure through lifestyle changes rather than medication, particularly benefiting older women who face different risk profiles than men.
Episode 190: Measles BasicsFuture Dr. Kapur explained the basics of measles, including the pathophysiology, diagnosis and management of this disease. Dr. Schlaerth added information about SPPE and told interesting stories of measles. Dr. Arreaza explained some statistics and histed the episode. Written by Ashna Kapur MS4 Ross University School of Medicine. Comments by Katherine Schlaerth, MD, and Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction.According to the CDC, as of April 24, 2025, a total of 884 confirmed measles cases were reported by 30 states, including California, and notably Texas. This is already three times more cases than 2024. There are 3 confirmed deaths so far in the US. What is measles?Measles is a disease that's been around for centuries, nearly eradicated, yet still lingers in parts of the world due to declining vaccination rates. Let's refresh our knowledge about its epidemiology, clinical features, diagnosis, management, and most importantly — prevention.Definition.Measles, also known as rubeola, is an acute viral respiratory illness caused by the measles virus. It's a single-stranded, negative-sense RNA virus belonging to the Paramyxoviridae family. It's extremely contagious with a transmission rate of up to 90% among non-immune individuals when exposed to an infected person.EpidemiologyBefore the introduction of the measles vaccine in 1963, nearly every child got measles by the time they were 15 years old. With the introduction of vaccination, cases and deaths caused by measles significantly declined. For example, in 2018, over 140,000 deaths were reported in the whole world, mostly among children under the age of 5.Measles is still a common disease in many countries, including in Europe, the Middle East, Asia, and Africa. Measles outbreaks have been reported recently in the UK, Israel, India, Thailand, Vietnam, Japan, Ukraine, the Philippines, and more recently in the US. So, let's take prevention seriously to avoid the spread of this disease here at home and abroad. How do we get measles, Ashna?Mode of Transmission:● Air: Spread primarily through respiratory droplets.● Surfaces: The virus remains viable on surfaces or in the air for up to 2 hours. (so, if a person with measles was in a room and you enter the same room within 2 hours, you may still get measles)● Other people: Patients are contagious from 4 days before until 4 days after the rash appears.PathophysiologyThe measles virus first infects the respiratory epithelium, replicates, and then disseminates to the lymphatic system.It leads to transient but profound immunosuppression, which is why secondary infections are common. It affects the skin, respiratory tract, and sometimes the brain, leading to complications like pneumonia or encephalitis.Clinical PresentationThe classic presentation of measles can be remembered in three C's:● Cough● Coryza (runny nose)● ConjunctivitisCourse of Disease (3 Phases):1. Prodromal Phase (2-4 days)○ High fever (can peak at 104°F or 40°C)○ The 3 C's○ Koplik spots: Small white lesions on the buccal mucosa.2. Exanthem Phase○ Maculopapular rash begins on the face (especially around the hairline), then spreads from head to toe. The rash typically combines into 1 big mass as it spreads, and the fever often persists during the rash.3. Recovery Phase○ Rash fades in the same order it appeared.○ Patients remain at risk for complications during and after rash resolution.Complications:● Pneumonia (most common cause of death in children)● Otitis media (most common overall complication)● Encephalitis (can lead to permanent neurologic sequelae)● Subacute sclerosing panencephalitis (SSPE): A rare, fatal, degenerative CNS disease that can occur years after measles infection.High-risk groups for severe disease include:● Infants and young children● Pregnant women● Immunocompromised individualsDiagnosisClinical diagnosis is sufficient if classic symptoms are present, especially in outbreak settings.Ashna: Laboratory confirmation:● Measles-specific IgM antibodies detected by serology.● RT-PCR from nasopharyngeal, throat, or urine samples.Notify public health authorities immediately upon suspicion or diagnosis of measles to limit spread. ManagementThere is no specific antiviral treatment for measles. Management is supportive:● Hydration (by mouth and only IV in case of severe dehydration)● Antipyretics (e.g., acetaminophen) for fever● Oxygen if hypoxicVitamin A supplementation:● Recommended for all children with acute measles, particularly in areas with high vitamin A deficiency. It has shown to reduce morbidity and mortality.Hospitalization may be necessary for:● Severe respiratory compromise● Dehydration● Neurologic complicationsPrevention: We live in perilous times and vaccination is under scrutiny right now. Before the measles vaccine, about 48,000 people were hospitalized and 400–500 people died in the United States every year. Measles was declared eradicated in the US in 2000, but the vaccination coverage is no longer 95%. How do we prevent measles?Vaccination is the cornerstone of prevention.● MMR vaccine (Measles, Mumps, Rubella):○ First dose at 12-15 months of age.○ Second dose at 4-6 years of age.○ 97% effective after 2 doses.The Advisory Committee on Immunization Practices (ACIP) has noted that febrile seizures typically occur 7 to 12 days after vaccination with MMR, with an estimated incidence of 3.3 to 8.7 per 10,000 doses. The Centers for Disease Control and Prevention (CDC) states that febrile seizures following MMR vaccination are rare and not associated with any long-term effects. The risk of febrile seizures is higher when the MMR vaccine is administered as part of the combined MMRV (measles, mumps, rubella, and varicella) vaccine compared to the MMR vaccine alone.Post-exposure prophylaxis:● MMR vaccine within 72 hours of exposure (if possible).● Immunoglobulin within 6 days for high-risk individuals (e.g., infants, pregnant women, immunocompromised).Herd immunity requires at least 95% vaccination coverage to prevent outbreaks.Key Takeaways● Measles is a highly contagious viral illness that can lead to severe complications.● Diagnosis is often clinical, but lab confirmation helps with public health tracking.● Treatment is mainly supportive, with Vitamin A playing a critical role in reducing complications.● Vaccination remains the most effective tool to eliminate measles worldwide.While measles might seem like a disease of the past, it can make a dangerous comeback without continued vigilance and vaccination efforts.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Centers for Disease Control and Prevention (CDC). Measles (Rubeola), Clinical Overview, July 15, 2024. Accessed on May 1, 2025. https://www.cdc.gov/measles/hcp/clinical-overview/index.html.World Health Organization (WHO). Measles, November 14, 2024. https://www.who.int/news-room/fact-sheets/detail/measlesGans, Hayley and Yvonne A. Maldonado, Measles: Clinical manifestations, diagnosis, treatment, and prevention, UpToDate, January 15, 2025. Accessed on May 1, 2025. https://www.uptodate.com/contents/measles-clinical-manifestations-diagnosis-treatment-and-preventionTheme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.
BUFFALO, NY - May 9, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on May 8, 2025, titled “METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." In this study, researchers Jayasree Peroth Jayaprakash, Pragati Karemore, and Piyush Khandelia from the Birla Institute of Technology and Science, India, discovered that a molecule called METTL3 contributes to the development and spread of oral squamous cell carcinoma (OSCC). The study shows that METTL3 increases the levels of a small RNA molecule called miR-146a-5p, which blocks SMAD4, a key tumor-suppressing gene. These findings help explain why oral cancers are difficult to treat and may offer a new target for more effective therapies. Oral squamous cell carcinoma is a common and aggressive cancer affecting the mouth and throat. It has a high death rate, mainly due to late detection, treatment resistance, and the cancer's ability to invade nearby tissues. In this study, the researchers focused on METTL3, an enzyme that adds chemical tags known as m6A marks to RNA, which change how genetic information is used by cells. They found that METTL3 is unusually active in OSCC cells, causing an increase in miR-146a-5p. This molecule, in turn, blocks the function of SMAD4, which helps control how cells grow and die in our bodies. “METTL3, the primary m6A RNA methyltransferase, is significantly upregulated in OSCC cells leading to increased global m6A levels.” When METTL3 was reduced or chemically blocked, miR-146a-5p levels dropped and SMAD4 levels increased. This shift slowed the growth of cancer cells, increased their death, and made them less likely to spread. When researchers reintroduced miR-146a-5p or lowered SMAD4 levels again, the cancer-promoting behavior returned. These results show that the METTL3–miR-146a-5p–SMAD4 pathway plays a key role in OSCC. The findings open up new possibilities for treatment. Drugs that block METTL3 or miR-146a-5p or that restore SMAD4 could slow or stop tumor growth. One such drug, STM2457, which targets METTL3, has already shown promise in lab studies. As research progresses, targeting this molecular pathway may offer a new strategy in treating OSCC. This discovery improves our understanding of how OSCC develops and avoids the body's defenses. By interfering with this newly discovered pathway, future treatments may become more successful, improving survival rates and quality of life for people with this disease. DOI - https://doi.org/10.18632/oncotarget.28717 Correspondence to - Piyush Khandelia - piyush.khandelia@hyderabad.bits-pilani.ac.in Video short - https://www.youtube.com/watch?v=o5XuDlcIma8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28717 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
A great idea isn't enough to build a thriving business—execution depends on how well a team works together. Miscommunication, misalignment, and unspoken tension can quietly stall progress, no matter how innovative the product is. The best founders aren't just visionaries; they know how to bring people together, translate ideas into action, and create an environment where momentum doesn't fade. Success often has less to do with the idea itself and more to do with the people making it happen. Dr. Kevin Scanlon has built a diverse career in academic medicine, pharmaceuticals, and biotech. He authored The Hybrid Entrepreneur, a guide to startup success, and has contributed to RNA research while mentoring university startups and investment groups. With a background in teaching entrepreneurship, he brings a deep understanding of business innovation and team dynamics. Today, he explores the challenges of turning scientific breakthroughs into business success. He emphasizes the need for clear communication, adaptable teams, and bridging the language gap between scientists, business leaders, and investors. Stay tuned! Resources: Connect with Kevin Scanlon on LinkedIn
In May 2025, we attended IMMUNOLOGY2025™, the annual meeting of the American Association of Immunologists in Honolulu, and recorded daily episodes discussing highlights of the previous 24 hours. Here is the second of five special episodes from the meeting. Brenda and Jason discuss highlights from sessions on tumor-infiltrating lymphocyte and T-cell receptor therapies, unconventional functions of Tregs, and advances in single-cell RNA sequencing.
What is measles - a refresher? Measles is a serious, highly contagious and potentially deadly viral infection. It is caused by an RNA paramyxovirus. It is spread by contact with droplets from an infected person's nose, mouth or throat. Sneezing and coughing can aerosolize the droplets and increase the range of infectious spread. Symptoms usually develop 8 to 10 days following exposure to an infected individual. A sick individual is contagious for 4 days before and 4 days after symptom onset. The reproductive rate is very high at 12+ meaning that 1 person will infect 12 and those 12 will get 12 more sick (144) and then 144 X 12 = 1728 X 12 = 20,736 and you are off to the exponential races....Plus, The Shock of a New Diagnosis: A Stoic Path Through the Storm. Enjoy, Dr. M
SJ Show Notes:Please support Shannon's independent network with your donation HERE:https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVT6Support Our Sponsors:You can get 20% off your first order of Blackout Coffee! Just head to http://blackoutcoffee.com/joy and use code joy at checkout.Be ready before you need it! Stock up now and protect your family. Go to https://www.allfamilypharmacy.com/JOY and use code JOY10 for 10% off your order.The Satellite Phone Store has everything you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/JoyThe 100% toxin free P600 sizzle set is 55% OFF for the SJ audience!! Go to https://www.chefsfoundry.com/joy today to claim the limited time discount!Get 45% OFF Native Path HYDRATE today! Special exclusive deal for the Joy audience only! Check it out HERE: www.nativepathhydrate.com/joyColonial Metals Group is the company Shannon trusts for all her metals purchases! Set up a SAFE & Secure IRA or 401k with a company who shares your values! Learn more HERE: https://colonialmetalsgroup.com/joyPlease consider Dom Pullano of PCM & Associates! He has been Shannon's advisor for over a decade and would love to help you grow! Call his toll free number today: 1-800-536-1368Or visit his website at https://www.pcmpullano.comTune in LIVE Today ——> https://rumble.com/v6srwiz-100-day-shocker-trump-is-deporting-fewer-illegal-immigrants-than-biden.htmlWatch LIVE TODAY and follow the SJ Show on Rumble HERE: https://rumble.com/c/TheShannonJoyShowShannon's Top Headlines April 30, 2025:BE PATIENT!!!: Trump's Economy Shrinks, Prices Soar, and the Blame Game Begins: https://croakycaiman.substack.com/p/be-patient-trumps-economy-shrinks?utm_source=post-email-title&publication_id=2855663&post_id=162537358&utm_campaign=email-post-title&isFreemail=false&r=fuu7w&triedRedirect=true&utm_medium=emailNumbers show no mass deportation of migrants, despite Trump immigration crackdown: https://x.com/Docjohnc/status/1894819606058922176Arcturus Therapeutics Receives U.S. FDA Fast Track Designation Self Amplifying RNA: https://www.biospace.com/press-releases/arcturus-therapeutics-receives-u-s-fda-fast-track-designation-for-the-starr-mrna-vaccine-candidate-arct-2304-for-pandemic-influenza-a-virus-h5n1The Reckless Gamble of Self-Amplifying RNA: A Runaway Experiment with No Off Switch: https://x.com/Docjohnc/status/1894819606058922176Is Self-Amplifying RNA a Synthetic Disease? https://therealcdc.substack.com/p/is-self-amplifying-rna-a-syntheticCLICK HERE To Stop The #DrDeath Bill In NYS: https://www.votervoice.net/AUTISMACTION/Campaigns/115959/Respond?unregistered=_ttc9anYD9aeEliyHNSITQYou really can't make this up …"Frankly I was shocked. They're lower, their daily average is simply 10 percent lower." This was according to Sue Long, a researchers who analyzed Trump's deportation statistics in the first 100 days of his presidency, comparing them to Biden era levels.This is another example of how the reality of Trump's first 100 days is drastically different than what Con Inc. & MAGA propagandists are pimping to their audiences.Meanwhile, as Trump gaslights his base on deportations, he is also fast tracking self amplifying mRNA shots to combat ‘bird flu' which is not only a continuation of Biden era health policies but an acceleration of potentially catastrophic biotechnology.Meet the new boss … same as the old boss. #UNIPARTYToday we are joined by two experts on the matter of emerging sa-RNA, the dangers of mRNA shots and government kill protocols, John Beaudoin Sr. and Jessica Rose. They will help us understand how this attempted merging of technology with biology is so dangerous and what we need to do to stop it.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
You're likely familiar with the genetic revolution — the discovery that physical structures in the cell, including DNA and RNA, shape every organism. But we are now overdue for another and more profound revolution in science, one you've likely heard very little about. Recent findings reveal that genetic and even epigenetic sources alone cannot account for the rich dynamism of life — not even close. Some other informational source is required. On this ID The Future, science writer and Discovery Institute Senior Fellow David Klinghoffer speaks with host Andrew McDiarmid about his new book Plato's Revenge: The New Science of the Immaterial Genome. It's a little book about a very big idea. It also tells the story of the scientist, Dr. Richard Sternberg, who has spent the last two decades bringing together cutting-edge molecular biology, higher mathematics, and commonsense reasoning to flesh out this potentially revolutionary new idea. Source
"If you are that person, if you feel like you can't find your box and you're off doing these random things that no one else seems to find interesting, it's okay. Embrace it. It's who you are and it's going to be your superpower someday." In this episode of The Biotech Startups Podcast, host Jon Chee sits down with Rabia Khan, founder and CEO of Serna Bio, to discuss her journey from Sensyne Health to building a data-driven biotech company pioneering RNA-targeted drug discovery. Rabia shares how she overcame scientific and operational hurdles, navigated contract research limitations, and boldly moved Serna Bio from the UK to San Francisco. She also reveals her intentional approach to company culture, frugality, and long-term impact—emphasizing her vision to create a biotech business built for enduring innovation, not just acquisition.
Discover the smallest motor in the universe—an astonishing molecular machine that powers all living cells with atomic precision. Explore why ATP synthase, with its near-perfect efficiency, challenges human engineering and evolutionary explanations. Dr Jonathan Sarfati explains how DNA’s replicating, repair, and detangling machines are vital for life. They are all encoded in the DNA, but the DNA can’t be decoded without these machines. This presents a “chicken-and-egg” paradox for naturalistic theories. DNA is also very unstable. Its presence in dinosaur bones undermine millions of years. RNA is 100× less stable than DNA, so could not be the first life. Evolutionists claim LUCA (Last Universal Common Ancestor) lived 4.2 billion years ago and already had 2.5 million DNA letters encoding 2,500 proteins. Life needed to start “very good” as Genesis 1:31 says. Otherwise, it would have crashed via error catastrophe.
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding and validating RNA therapies for chronic liver diseases.
Desde hace décadas, los científicos estudian qué genes a lo largo de la evolución han sido los más importantes para que los humanos hablemos. Hasta ahora, el principal candidato era el gen llamado FOXP2. Los humanos poseemos una variante del gen FOXP2 que no poseen otros animales relacionados con nosotros, en particular no la poseen chimpancés o gorilas. Esta aparente exclusividad humana hizo creer en un principio que esa variante de FOXP2 era la que nos capacitaba para hablar. Gracias a los progresos en la secuenciación del DNA se ha podido obtener y comparar la secuencia de especies humanoides, como neandertales y denisovanos, así como de gorilas, chimpancés, orangutanes y bonobos. A partir de la comparación de esos genomas, se han identificado 61 genes cuyas variantes aparecen exclusivamente en la especie humana. Una de estas variantes génicas ha atraído mucho la atención de los científicos. Se trata de una variante del gen NOVA1, que produce una proteína que interacciona con el RNA en las neuronas y modula su función.
What does it take to go from humble beginnings to billionaire status while revolutionizing health and technology? In this episode of The Thrive State Podcast, Dr. Kien Vuu sits down with Naveen Jain, the visionary entrepreneur behind Viome, Moon Express, and other billion-dollar companies, to discuss mindset, health, AI, and longevity. Episode Highlights: From rags to billionaire – Meet Naveen Jain The #1 mindset shift that makes success inevitable Why entrepreneurs should never compete—only disrupt How AI is transforming healthcare (Detecting disease before symptoms appear!) The gut-brain connection and how it impacts mental health
In this episode, Dr. Robert Malone, highlights his scientific career, personal experiences, and controversial perspectives on COVID-19 and RNA technology. Dr. Malone has been a significant figure in the Freedom Movement, especially notable after appearing on the Joe Rogan Experience in 2021. He discusses his background, growing up in California, and how his upbringing in a tech and military-industrial complex environment influenced his career. Dr. Malone delves into his pioneering work in mRNA technology, the contentious patent disputes, and his journey through academia and biodefense sectors, which led to significant roles during pandemics like Zika and COVID-19. The conversation covers his interactions with CIA operatives, his contributions to early COVID-19 treatments, and his journey through intense public and media scrutiny after expressing dissenting views on COVID-19 vaccines. He explains the concept of fifth and sixth generation warfare and its implications. Dr. Malone also talks about his efforts in homesteading and community building as a form of resilience against modern socioeconomic pressures. Connect with Dr. Malone here: X Website Substack Malone Media Our Sponsors: Let's level up your nicotine routine with Lucy. Go to Lucy.co/KKP and use promo code (KKP) to get 20% off your first order. Lucy offers FREE SHIPPING and has a 30-day refund policy if you change your mind. With Happy Hippo, you're getting a product that's been sterilized of pathogens, tested for impurities and heavy metals, and sold with a guarantee. Go to happyhippo.com/kkp and use Code KKP for 15% off the entire store Organifi.com/kkp and grab a Sunrise to Sunset kit to be covered with Red, Green and Gold, with 20% off using code KKP Fast Growing Trees makes it easy to get your dream yard. Order online and get your plants delivered directly to your door in just a few days, without ever leaving home. Click here to order! Connect with Kyle: I'm back on Instagram, come say hey @kylekingsbu Twitter: @kingsbu Fit For Service Academy App: Fit For Service App Our Farm Initiative: @gardenersofeden.earth Odysee: odysee.com/@KyleKingsburypod Youtube: Kyle Kingbury Podcast Kyle's Website: www.kingsbu.com - Gardeners of Eden site If you enjoyed this podcast, please subscribe & leave a 5-star review with your thoughts!
They told her she would never succeed, now her work has saved millions. In this episode, Ryan talks with Dr. Katalin Karikó, the scientist behind the mRNA technology that led to COVID-19 vaccines. She grew up in rural Communist Hungary, faced rejection after rejection, got demoted, and struggled financially but she never stopped chasing the science. Dr. Katalin Karikó opens up to Ryan about her experiences as an immigrant in the U.S., the grind of scientific discovery, enjoying the process rather than focusing solely on outcomes, misinformation in the scientific community, and the responsibility of scientists to communicate effectively with the public.Dr. Katalin Karikó is a Hungarian American biochemist who specializes in RNA-mediated mechanisms. She won the 2023 Nobel Prize in Physiology or Medicine with her colleague Dr. Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19. Read the New York Times feature on Dr. Katalin Karikó hereFollow Dr. Katalin Karikó on Instagram @katalin_kariko Check Dr. Katalin Karikó's memoir Breaking Through: My Life in Science
© 2020-2025 Ivy Podcast Discovery LLC
